Published October 2005 | Version v1
Journal article

Preliminary clinical application of 11C-MET PET/CT in the brain glioma patients

  • 1. PET Center, Nanfang Hospital, Southern Medical Univ., Guangzhou (China)

Description

Objective: To study the clinical value of 11C-methionine (MET) PET/CT imaging in brain glioma. Methods: 27 cases were studied including 2 glioma, 23 operated glioma and 2 healthy volunteers. 11C-MET PET/CT was performed in all cases but 18F-fluorodeoxyglucose (FDG) PET/CT in only 17 cases. Follow-up period was within 3-17 months. Results: 11C-MET was negative in 4 cases and 18F-FDG negative in 3 cases in group without remnant or recurrent tumor after operation. In 2 cases of initial glioma and 19 cases with remnant or recurrent tumor group, 11C-MET imaging was positive in 20 cases, tumor/gray matter ratio and tumor/white matter ratio were 2.02 ± 0.96, 3.01 ± 1.79, respectively, among them 14 cases also with 18F-FDG imaging showed positive in 12 cases. Lesions showed by 11C-MET were far more clear than that of 18F-FDG. Also tumor/gray matter ratio and the tumor/white matter ratio of 11C-MET imaging were significantly higher than 18F-FDG (2.15 ± 1.16 vs 0.97 ± 0.43, P<0.01; 3.31 ± 2.16 vs 1.90 ± 0.67, P<0.05 ). Conclusion: 11C-MET PET/CT is superior to 18F-FDG PET/CT in the diagnosis and localization of brain glioma. (authors)

Additional details

Publishing Information

Journal Title
Chinese Journal of Nuclear Medicine
Journal Volume
25
Journal Issue
5
Journal Page Range
p. 286-287
ISSN
0253-9780

Optional Information

Notes
4 refs.